sprite-preloader
Anzeige
Mehr »
Sonntag, 18.11.2018 Börsentäglich über 12.000 News von 598 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen
13.07.2018 | 16:46
(6 Leser)
Schrift ändern:
(0 Bewertungen)

PR Newswire·Mehr Nachrichten von PR Newswire

LONDON, July 13, 2018 /PRNewswire/ --

Mammalian Cell Cultures, Microbial Fermentations, Other Expression Systems, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines

The biological drug API manufacturing market is estimated to grow at a CAGR of 9.0% in the first half of the forecast period. In 2017, Mammalian cell culture systems submarket represents the largest submarket within the biological drug API manufacturing industry.

(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this 209-page report delivers:

• Provides qualitative and quantitative analysis of the leading submarkets the period 2018-2028. Visiongain forecasts revenues and their growth for these submarkets:
• Mammalian cell culture
• Microbial fermentation
• Other expression platforms

• Provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2018-2028. Visiongain forecasts contract API drug revenues to 2028 for these individual segments:
• Monoclonal antibody (mAb) therapies
• Vaccines
• Insulin therapies
• Interferon therapies
• Growth hormones

• Find forecasts of the leading national markets from 2018 to 2028:
• The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
• The US
Japan
Switzerland
• Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.

• Profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
• Boehringer Ingelheim BioXcellence
• Celltrion
• DSM Biologics
• Lonza
• Samsung BioLogics
• Cytovance Biologics
• Fujifilm Diosynth Biotechnologies
• Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.

• Provides qualitative analysis: SWOT and STEP Analysis of the biological drug API manufacturing market.

• Discover the regulatory outlook for biotech API manufacturing in leading regional and national markets in 2017, as well as predicted developments for the period to 2028.

• Identify important drug development and technology trends that will affect CMOs, their clients and other market participants from 2017. The report also contains SWOT and STEP analysis of the industry and market.

• Find profiles for leading CMOs offering biological drug API manufacturing services to pharmaceutical companies.

• 103 charts unavailable elsewhere

Visiongain's study is intended for anyone requiring commercial analyses for the biological drug API manufacturing market. You find data, trends and predictions.

Buy our report today Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028: Mammalian Cell Cultures, Microbial Fermentations, Other Expression Systems, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/biological-drug-api-manufacturing-services-world-industry-and-market-predictions-2018-2028

Abasria
AbbVie
Accord Healthcare
Acquired Cedarburg Pharmaceuticals,
Actavis Generics
Adaptimmune Therapeutics
Agensys
Althera Technologies
Altus Pharmaceuticals
Amgen
Apotex
Aptuit
arGEN-X
Ascendis Pharma A/S
Asterion
Astra Zeneca
Avid Bioservices Inc
Bakhu Pharma.
Banner Life Sciences
Basaglar
Baxalta
Baxter
Bayer
Bever Pharmaceutical
Biocad
Biocon
Biogen
Biogen Idec
BMS
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence
Bolder BioTechnology
Calico Life Science
Caspugel
Catalent Biologics
Celgene
Celldex Therapautics
Celltrion
Cinfa
CMC Biologics
CMIC Holdings Co. Ltd.
CMO Relthy Laboratórios
Cook Pharmica
Critical Pharmaceuticals
CT Arzneimittel
Cytos Biotechnology
Cytovance Biologics
DPx Fine Chemicals
DPx Holdings B.V.
DSM Biologics
DSM Sinochem Pharmaceuticals
Eli Lily
EMD Millipore
Ferring Pharmaceuticals
Filnox Biotech
Fresenius
Fujifilm Diosynth Biotechnologies
Gallus BioPharmaceuticals,
GE Healthcare
Genentech
GeneScience Pharmaceuticals Co., Ltd.
Genexine and Handok
Genmab
Genzyme
Gilead Sciences, Inc.
GSK
Hanmi Pharmaceutical Co.
Hexal
Index Ventures
Infarco
Infinity Pharmaceuticals
Inno Biologics
Innovation Network Corporation of Japan (INCJ),
Johnson and Johnson
Johnson Matthey
JSR Corporation
Kalon Biotherapeutics
KBI Biopharma, Inc.
Kemwell
Kyowa Hakko Kirin
Labrys Biologics Inc,
Laureate Biopharma
LG Life Sciences, Ltd.
Lonza
Matrix Laboratories
Merck
Mitsubishi Gas Chemical Company
Mylan
Neopharm
Nikon
Nippon kayaku
Norbitec
Novartis
Novasep
Novo Nordisk
Nuron Biotech
Nycomed
Opko Health
Patheon
PelChem
Peregrine Pharmaceuticals
Perrigo
Pfizer
Pharmstandard
Phyton Biotech
Piramal Healthcare
Precision Biologics
Progenics
Quintiles
Rebtschler Biotechnologie
Recepta Biopharma
Redwood Bioscience
Rentschler
Rentschler Biotechnologie
Roche
RoYal DSM
SAFC
Samsung BioLogics
Sanofi
SCM Pharma
Seattle Genetics
ShangPharma
SICOR Biotech
Sigma-Aldrich Corporation
Stada
SunShine Biopharma
SynCo BioPartners
Takeda
Teva
Therapure Biopharma
Thermo Fisher
Toyobo Biologics
Transgene SA
Versartis
Vertex
Vida Pharma
VTU
WuXi Biologics,
WuXi PharmaTech
Zhangjiang Biotech
Zhejiang Jiang Yuan Tang Biotechnology
ZJ Base

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com



© 2018 PR Newswire